Overview of recent advances in metastatic triple negative breast cancer

Table 2 Immunotherapy as a monotherapy in metastatic triple negative breast cancer

Trial	n	Drug	ORR 1st line	ORR ≥ 1 prior line	Median OS (mo) 1st line	Median OS (mo) ≥ 1 line	Ref.
NCT01375842 Phase Ia	116	Atezolizumab	24%	6%	17.6	7.3	Emens et al[52], 2019
KEYNOTE-012 Phase Ib	32	Pembrolizumab		18.5		11.2	Nanda et al[50], 2016
JAVELIN/Phase Ib	58	Avelumab		5.2		9.2	Dirix et al[51], 2018
KEYNOTE-086 Phase II	170	Pembrolizumab	23.1%	5.3	18.0	9.0	Adams et al[53], 2019
KEYNOTE-119/Phase III	622	Pembrolizumab vs chemo		9.6 vs 10.6		CPS ≥ 1; 10.7 vs 10.2. CPS ≥10; 12.7 vs 11.6. CPS ≥ 20; 14.9 vs 12	Verret et al[83], 2019

ORR: Overall response rate; OS: Overall survival; CPS: Combined positive score.